在肝细胞癌（HCC）进展过程中，研究人员观察到多个细胞色素 P450（CYP）家族基因表达受到抑制，并且关键的生理代谢过程如“羧酸代谢、烯烃化合物代谢和类固醇代谢”出现显著紊乱。尤其是，研究人员鉴定出五个与 HCC 进展高度相关的显著上调差异表达基因 ...

A recent study conducted by the Guangzhou Institutes of Biomedicine and Health (GIBH) of the Chinese Academy of Sciences (CAS ...

Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality.

The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 ...

Two new studies represent a big step toward developing innovative molecular therapies capable of disrupting the ...

XPOVIO® is the first XPO1 inhibitor approved in Taiwan for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM). After the mainland of China, South Korea, Australia and ...

Detailed price information for Cogent Biosciences Inc (COGT-Q) from The Globe and Mail including charting and trades.

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “A case report of donor cell–derived ...

Zenocutuzumab helps fill an important need for patients with advanced pancreatic cancer and NSCLC with NRG1 gene fusions, said Alison Schram M.D., ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length ...